Cobalt-alkyne complexes with imidazoline ligands as estrogenic carriers: Synthesis and pharmacological investigations

Journal of Medicinal Chemistry

Volumn 51, Issue 22, 2008, Pages 7318-7322

  Schlenk, Miriam ^a   Ott, Ingo ^a   Gust, Ronald ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYNE DERIVATIVE; ANTINEOPLASTIC AGENT; COBALT DERIVATIVE; ESTROGEN RECEPTOR ALPHA; HUMAN SERUM ALBUMIN; IMIDAZOLINE DERIVATIVE; N PROPARGYL 4,5 BIS(2 CH1ORO 4 METHOXYHYDROXYPHENY1) 2 IMIDAZOLINE; N PROPARGYL 4,5 BIS(2 CHLORO 4 HYDROXYPHENYL) 2 IMIDAZOLINE]HEXACARBONYLDICOBALT; PROPARGYL 4,5 BIS(2 CHLORO 4 METHOXYPHENYL) 2 IMIDAZOLINE]HEXACARBONYLDICOBALT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL;

ALKYNES; CELL LINE, TUMOR; CELL PROLIFERATION; COBALT; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGEN RECEPTOR ALPHA; ESTROGENS; HUMANS; IMIDAZOLINES; LIGANDS; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; STEREOISOMERISM; TIME FACTORS;

EID: 56749165090     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8008376     Document Type: Article

References (18)

1. Jung, M.; Kerr, D. E.; Senter, P. D. Bioorganometallic chemistry-synthesis and antitumor activity of cobalt carbonyl complexes. Arch. Pharm. Pharm. Med. Chem. 1997, 330, 173-176.
2. Schmidt, K.; Jung, M.; Keilitz, R.; Schnurr, B.; Gust, R. Acetylene-hexacarbonyldicobalt complexes, a novel class of antitumor drugs. Inorg. Chim. Acta 2000, 306, 6-16.
3. Roth, T.; Eckert, C.; Fiebig, H. H.; Jung, M. Comparative action of cobalt carbonyl complexes on cancer cells using human tumor xemografts. Anticancer Res. 2002, 22, 2281-2284.
4. Ott, I.; Kircher, B.; Gust, R. Investigations on the effects of cobalt-alkyne complexes on leukaemia and lymphoma cells: cytotoxicity and cellular uptake. J. Inorg. Biochem. 2004, 98, 485-489.
5. Vessières, A.; Top, S.; Vaillant, C.; Osella, D.; Mornon, J.-P.; Jaouen, G. Carbonylmetallcluster-modofizierte Östradiole als Suizidsubstrate zur Untersuchung von Rezeptorproteinen: Anwendung beim Östradiol-Rezeptor. Angew. Chem. 1992, 104, 790-792.
6. Osella, D.; Cavigiolio, G.; Vincenti, M.; Vessières, A.; Laios, I.; Leclercq, G.; Napoletano, E.; Fiaschi, R.; Jaouen, G. The first organometallic derivative of 11β-ethynylestradiol, a potential high-affinity marker for the estrogen receptor. J. Organomet. Chem. 2000, 596, 242-247.
7. Osella, D.; Ravera, M.; Nervi, C.; Cavigliolio, G.; Vinceti, M.; Vessières, A.; Jaouen, G. Stabilization of carbenium ions derived from ethynylestradiol by different adjacent organometallic moiety. Implication in the inactivation of the estrogen receptor. Eur. J. Inorg. Chem. 2000, 49, 1-497.
8. Gust, R.; Keilitz, R.; Schmidt, K. Investigations of new lead structures for the design of selective estrogen receptor modulators. J. Med. Chem. 2001, 44, 1963-1970.
9. von Rauch, M.; Schlenk, M.; Gust, R. Effects of C2-alkylation, N-alkylation and N,N′-dialkylation on the stability and estrogen receptor interaction of (4R,5S)/(4S,5R)-4, 5-bis(4-hydroxyphenyl)-2-imidazolines. J. Med. Chem. 2004, 47, 915-927.
10. von Rauch, M.; Busch, S.; Gust, R. Investigations on the effects of basic side chains on the hormonal profile of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl-2-imidazolines. J. Med. Chem. 2005, 48, 466-474.
11. Kekenes-Huskey, P. M.; Muegge, I.; von Rauch, M.; Gust, R.; Knapp, E.-W. A molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophores. Bioorg. Med. Chem. 2004, 12, 6527-6537.
12. Hafner, F.; Holler, E.; von Angerer, E. Effect of growth factors on estrogen receptor mediated gene expression. J. Steroid Biochem. Mol. Biol. 1996, 58, 385-393.
13. Ott, I.; Schmidt, K.; Kircher, B.; Schumacher, B.; Wiglenda, T.; Gust, R. Antitumor-active cobalt-alkyne complexes derived from acetyl-salicylic acid: studies on the mode of drug action. J. Med. Chem. 2005, 48, 622-629.
14. Ott, I.; Gust, R. Stability, protein binding and thiol interaction studies on [2-acetoxy-(2-propynyl)benzoate]hexacarbonyldicobalt. Biometals 2005, 18, 171-177.
15. Gust, R.; Busch, S.; Keilitz, R.; Schmidt, K.; von Rauch, M. Investigations on the influence of halides substituents on the estrogen receptor interaction of 2,4,5-triarylimidazoles. Arch. Pharm. Pharm. Med. Chem. 2003, 336, 456-465.
16. Bernhardt, G.; Reile, H.; Birnböck, H.; Spruss, T.; Schönenberger, H. Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. Res. Clin. Oncol. 1992, 118, 35-43.
17. Reile, H.; Birnböck, G.; Bernhardt, G.; Spruss, T.; Schönenberger, H. Computerized determination of growth kinetic curves and doubling times from cells in microculture. Anal. Biochem. 1990, 187, 262-267.
18. Gust, R.; Schnurr, B.; Krauser, R.; Bernhardt, G.; Koch, M.; Schmid, B.; Hummel, B.; Schönenberger, H. Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)ethylendiamine]-[cyclobutane-1, 1-dicarboxylato]platinum(II), a novel, highly active carboplatin derivative. J. Cancer Res. Clin. Oncol. 1998, 124, 585-597.